Growth Hormone Secretagogues Compared

Growth hormone (GH) secretion is governed by a neuroendocrine cascade known as the somatotropic axis. The hypothalamus produces two opposing signals: growth hormone-releasing hormone (GHRH), which stimulates GH release from anterior pituitary somatotroph cells, and somatostatin (SST), which inhibits it. Once secreted, GH acts on hepatocytes in the liver to stimulate production of insulin-like growth factor 1 (IGF-1), which mediates many of the downstream anabolic effects attributed to GH.

The axis operates through a negative feedback loop: elevated IGF-1 and GH suppress hypothalamic GHRH release and stimulate somatostatin, maintaining homeostasis. GH is released in a pulsatile pattern, with the largest bursts occurring during slow-wave sleep. Growth hormone secretagogues are compounds that amplify or initiate these pulses through one of two receptor pathways, forming the basis for two distinct pharmacological classes.

All GH secretagogues act through one of two receptor systems on pituitary somatotrophs:

**GHRH Receptor (GHRHR) Pathway** — GHRH analogs bind the GHRH receptor, a G-protein coupled receptor that activates adenylate cyclase and raises intracellular cAMP. This stimulates GH gene transcription, GH synthesis, and exocytosis of stored GH granules. Compounds in this class include CJC-1295, Sermorelin, and Tesamorelin.

**Ghrelin / Growth Hormone Secretagogue Receptor (GHS-R1a) Pathway** — Growth hormone-releasing peptides (GHRPs) bind the ghrelin receptor (GHS-R1a), activating phospholipase C and the IP3/DAG cascade to raise intracellular calcium. This triggers GH release through a mechanism independent of cAMP. Compounds in this class include Ipamorelin, GHRP-6, and Hexarelin.

Because these two pathways converge on different intracellular signaling cascades, co-administration of a GHRH analog and a GHRP produces a synergistic — not merely additive — GH response. Research by Bowers et al. demonstrated that combining GHRH with GHRP-6 produced GH peaks roughly 10-fold higher than either compound alone.

GHRH analogs mimic the action of endogenous GHRH(1-44) or its truncated active fragment GHRH(1-29). They stimulate both the synthesis and secretion of GH, preserving the natural pulsatile release pattern.

**Sermorelin (GRF 1-29)** — The shortest analog, consisting of the first 29 amino acids of native GHRH. It has a short half-life of approximately 10-20 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). Sermorelin was FDA-approved in 1997 for diagnosis and treatment of GH deficiency in children (marketed as Geref), though it was later withdrawn from the market for commercial reasons, not safety concerns. It is considered the most physiological GHRH analog, producing GH pulses that closely mimic endogenous secretion.

**CJC-1295 (Modified GRF 1-29)** — A synthetic analog of GHRH(1-29) with four amino acid substitutions (Ala2, Ala8, Ala15, Leu27) that confer DPP-IV resistance. Without Drug Affinity Complex (DAC), the half-life extends to approximately 30 minutes. With DAC — a maleimidopropionic acid linker that binds albumin in vivo — the half-life extends to 6-8 days. The DAC version produces sustained GH and IGF-1 elevation rather than pulsatile release, which some researchers consider less physiological.

**Tesamorelin (Egrifta)** — A modified GHRH(1-44) analog with a trans-3-hexenoic acid moiety attached to the tyrosine at position 1. This modification improves metabolic stability while retaining full GHRHR agonist activity. Tesamorelin has a half-life of approximately 26 minutes and is the only GHRH analog with current FDA approval, indicated for reduction of excess abdominal fat in HIV-associated lipodystrophy (approved 2010). It is notable for selectivity in reducing visceral adipose tissue without significantly affecting subcutaneous fat.

Growth hormone-releasing peptides activate the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons. Unlike GHRH analogs, GHRPs also suppress somatostatin release, effectively removing the brake on GH secretion. Individual GHRPs differ significantly in potency, selectivity, and off-target effects.

**Ipamorelin** — A pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the most selective GHRP identified. It stimulates GH release in a dose-dependent manner without significantly affecting cortisol, prolactin, or aldosterone at standard research doses. It does not strongly stimulate appetite (unlike GHRP-6), making it the preferred GHRP for protocols where appetite stimulation is undesirable. Half-life is approximately 2 hours.

**GHRP-6** — A hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that produces robust GH release but with notable off-target effects. GHRP-6 significantly stimulates appetite through ghrelin receptor activation in the hypothalamic arcuate nucleus, increases cortisol and prolactin at higher doses, and can elevate gastric motility. It is considered a more potent but less selective GH secretagogue than Ipamorelin. Half-life is approximately 15-60 minutes.

**Hexarelin** — The most potent GHRP by peak GH amplitude. Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) produces the largest acute GH release of any GHRP but is subject to significant tachyphylaxis — the GH response diminishes with repeated administration over days to weeks. It also raises cortisol and prolactin more than other GHRPs and has documented cardioprotective properties through binding to the CD36 scavenger receptor independently of GH release. Half-life is approximately 70 minutes.

The most studied secretagogue strategy in clinical research is co-administration of a GHRH analog with a GHRP. The mechanistic rationale is two-fold: (1) GHRH analogs directly stimulate GH synthesis and release through cAMP, while (2) GHRPs amplify the GH pulse by suppressing somatostatin and activating an independent intracellular calcium pathway.

Bowers et al. (1990) first demonstrated this synergy, showing that combined GHRH + GHRP-6 administration produced GH peaks roughly an order of magnitude greater than either peptide alone. This finding has been replicated across multiple GHRH/GHRP pairings.

The most commonly studied combination in current research is CJC-1295 (no DAC) + Ipamorelin. This pairing is favored because both compounds are relatively selective: CJC-1295 does not significantly affect cortisol or prolactin, and Ipamorelin is the most selective GHRP. The combination produces robust, pulsatile GH release with minimal off-target hormonal effects.

Timing is relevant in research protocols. GH release is greatest when secretagogues are administered during periods of low somatostatin tone — typically upon waking, post-exercise, or before sleep. Administration with food (particularly fats and carbohydrates) blunts the GH response due to insulin-mediated somatostatin release and elevated free fatty acids.

Other studied pairings include Sermorelin + GHRP-6 (used when appetite stimulation is a desired outcome) and Tesamorelin + Ipamorelin (combining FDA-approved GHRH analog with the most selective GHRP).

| Compound | Class | Receptor | Half-Life | GH Potency | Cortisol Effect | Prolactin Effect | Appetite Stimulation | Notable Feature | |---|---|---|---|---|---|---|---|---| | CJC-1295 (no DAC) | GHRH analog | GHRHR | ~30 min | Moderate | None | None | None | DPP-IV resistant, pulsatile release | | CJC-1295 (DAC) | GHRH analog | GHRHR | 6-8 days | High (sustained) | None | None | None | Albumin-binding, sustained IGF-1 | | Sermorelin | GHRH analog | GHRHR | 10-20 min | Moderate | None | None | None | Most physiological, former FDA approval | | Tesamorelin | GHRH analog | GHRHR | ~26 min | Moderate-High | None | None | None | FDA-approved for lipodystrophy | | Ipamorelin | GHRP | GHS-R1a | ~2 hr | Moderate | Minimal | Minimal | Minimal | Most selective GHRP | | GHRP-6 | GHRP | GHS-R1a | 15-60 min | High | Moderate increase | Moderate increase | Strong | Potent but less selective | | Hexarelin | GHRP | GHS-R1a | ~70 min | Highest (acute) | Significant increase | Significant increase | Moderate | Most potent, tachyphylaxis, cardioprotective |

Tesamorelin (brand name Egrifta) holds a unique position among GH secretagogues as the only compound in either class with current FDA approval. It was approved in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution associated with antiretroviral therapy.

The approval was based on two pivotal Phase III trials (Study 1 and Study 2) involving 816 HIV-positive patients with excess abdominal fat. At 26 weeks, tesamorelin reduced trunk fat by approximately 15-18% compared to placebo, with corresponding reductions in waist circumference and improvements in patient-reported body image. Notably, the reduction was predominantly in visceral adipose tissue (VAT), with minimal effect on subcutaneous fat or limb fat.

Subsequent research has explored tesamorelin beyond lipodystrophy. The HATIM trial investigated its effects on hepatic fat in HIV patients and found significant reductions in liver fat fraction. Studies have also examined its effects on cognitive function, with the FIGHT trial showing improvements in executive function and verbal memory in cognitively normal older adults — a finding linked to IGF-1-mediated neuroprotection.

Tesamorelin maintains the pulsatile GH release pattern and does not suppress endogenous GH production. In clinical trials, IGF-1 levels remained within the normal physiological range in the majority of treated subjects.

GH secretagogues are active areas of investigation across multiple research domains:

**Body composition** — Both GHRH analogs and GHRPs have been studied for effects on lean mass accretion and visceral fat reduction. Tesamorelin's FDA approval for lipodystrophy validated the principle. Research continues into whether similar effects extend to age-related body composition changes.

**Age-related GH decline** — GH secretion declines approximately 14% per decade after age 30 (somatopause). Secretagogues that restore pulsatile GH release without supraphysiological peaks are studied as potential interventions for age-related sarcopenia, osteopenia, and metabolic changes.

**Sleep architecture** — GH pulses are tightly coupled to slow-wave sleep. GHRH analogs administered before sleep have been shown to increase slow-wave sleep duration in research settings, suggesting bidirectional regulation between the somatotropic axis and sleep.

**Neuroprotection** — IGF-1 is a key neurotrophic factor. Tesamorelin research in older adults has shown cognitive benefits, and GHRP-6 has been studied for neuroprotective properties in ischemic brain injury models in rodents.

**Cardioprotection** — Hexarelin binds the CD36 scavenger receptor on cardiac tissue independently of GH release. In vitro and animal studies have shown hexarelin reduces cardiac fibrosis and protects against ischemia-reperfusion injury.

**Wound healing and recovery** — GH and IGF-1 are involved in tissue repair. Secretagogue combinations are studied in animal models of fracture healing, tendon repair, and post-surgical recovery.

All applications described here are based on published research. These compounds are sold for research purposes only and are not approved for general clinical use except where noted (tesamorelin for HIV-associated lipodystrophy).